Trials Sponsors Conditions Drugs Pricing

Conditions

Melanoma

Keywords

MelanomaCancer

Outcome Measures

Primary Outcomes (1)

Number of participants that possess circulating tumor cells.
14-21 days

Study Arms (3)

Healthy control subjects

Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.

Advanced-Stage Melanoma

To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.

Early-Stage Melanoma

To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts.

You may qualify if:

Age 18 to 80 years

Sponsors & Collaborators

University of Arkansas
Otherlead

Study Sites (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

RECRUITING

Jumin Sunde, MDCONTACT501-603-1214 JSunde2@uams.edu

Jumin SundePRINCIPAL INVESTIGATOR

Sajjad BhattiSUB INVESTIGATOR

MeSH Terms

Conditions

MelanomaNeoplasms

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Jumin Sunde, MD
University of Arkansas
PRINCIPAL INVESTIGATOR

Central Study Contacts

Jumin Sunde, MD

CONTACT

501-526-6990 Jsunde2@uams.edu

Daniel Dunham

CONTACT

5016868274

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 14, 2013

First Posted

January 28, 2013

Study Start

February 2013

Actual (reported)

Primary Completion

July 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

In Vivo Real-time Detection of Circulating Melanoma Cells

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Healthy control subjects

Advanced-Stage Melanoma

Early-Stage Melanoma

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Healthy control subjects

Advanced-Stage Melanoma

Early-Stage Melanoma

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations